Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rate, Phase 3 Data Show

Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rate, Phase 3 Data Show

Novice o hemofiliji danes

Image

Please enable the javascript to submit this form

Podprto z izobraževalnimi štipendijami Bayerja, BioMarina, CSL Behringa, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics in uniQure, Inc.

Bistveni SSL